New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:13 EDTMNKD, SNYSanofi, MannKind announce global licensing agreement for Afrezza
Sanofi (SNY) and MannKind (MNKD) announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in 1Q15. Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities. Under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. In addition, the companies are planning to collaborate to expand manufacturing capacity to meet global demand as necessary. Under the terms of the agreement, MannKind will receive an upfront payment of $150M and potential milestone payments of up to $775M. The milestone payments are dependent upon specific regulatory and development targets, as well as sales thresholds. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi has agreed to advance to MannKind its share of the collaboration's expenses up to a limit of $175M.
News For SNY;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTMNKDPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
December 8, 2014
05:50 EDTMNKDStocks with implied volatility movement; AVNR MNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use